ZMC(SH:600216) Xin Lang Cai Jing·2025-08-26 03:11Core Insights - Zhejiang Pharmaceutical (600216.SH) reported a total operating revenue of 4.323 billion yuan, ranking 13th among disclosed peers [1] - The net profit attributable to shareholders reached 673 million yuan, ranking 7th among disclosed peers, with a year-on-year increase of 358 million yuan, representing a 113.52% growth compared to the same period last year [1] - The net cash inflow from operating activities was 798 million yuan, ranking 6th among disclosed peers, with a year-on-year increase of 589 million yuan, reflecting a 281.20% growth compared to the same period last year [1] Financial Ratios - The latest debt-to-asset ratio is 19.80%, ranking 31st among disclosed peers, a decrease of 0.65 percentage points compared to the same period last year [3] - The latest gross profit margin is 39.82%, an increase of 4.42 percentage points year-on-year, marking two consecutive years of growth [3] - The latest return on equity (ROE) is 6.00%, ranking 20th among disclosed peers, with an increase of 2.83 percentage points compared to the same period last year [3] Earnings Per Share and Turnover - The diluted earnings per share (EPS) is 0.70 yuan, ranking 11th among disclosed peers, with an increase of 0.37 yuan year-on-year, representing a 112.12% growth compared to the same period last year [3] - The latest total asset turnover ratio is 0.31 times, ranking 14th among disclosed peers [3] - The latest inventory turnover ratio is 1.20 times, ranking 39th among disclosed peers [3] Shareholder Structure - The number of shareholders is 65,500, with the top ten shareholders holding 489 million shares, accounting for 50.88% of the total share capital [3] - The largest shareholder is Xinchang Changxin Investment Development Co., Ltd., holding 21.65% of the shares [3] - Other significant shareholders include Guotou High-tech Investment Co., Ltd. (15.61%) and Hong Kong Central Clearing Limited (7.41%) [3]